RxDoctor Payments Data

Pramila Daftary, MD

Allergy/ Immunology · Waco, TXNPI 1255399945

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,916 of the $2,558 with a category attached, or 74.9%. 19 manufacturers reported payments, led by Shionogi Inc at 30.5% of the total. Reporting peaked in 2020 at $1,043 and has fallen 87.6% since, to $129 in 2025.

$2,558in general payments, 2019–2025

Across 102 payments — averaging $25.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shionogi Inc$781
  • GSK$366
  • Pfizer$180
  • Novartis$170
  • AstraZeneca$164
  • Regeneron Healthcare Solutions, Inc.$154
  • plus $744 from 13 others
$192,298in research payments, 2019–2025

Across 42 payments — averaging $4578.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$113K
  • Shionogi Inc$35K
  • GSK$18K
  • Novartis$15K
  • Pfizer$8K
  • AstraZeneca$4K

What the payments were for

  • Travel & lodging$64225%
  • Food & beverage$1,91675%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few allergy/ immunology providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$277,682
Medicare patients
367
Services billed
18,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol23$22,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,949
Montelukast Sodium279$2,850
Albuterol Sulfate HfaAlbuterol Sulfate67$1,452
Azelastine Hcl62$1,386
Ipratropium Bromide28$1,254
Fluticasone Propionate89$1,109
Doxycycline Monohydrate25$182
Azithromycin26$101
Amoxicillin14$64
Levocetirizine Dihydrochloride14$43
Famotidine12$27
Prednisone20$21

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$164$22,90223 claims
GSKTrelegy Ellipta$366$13,94919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Texason file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →